Atopic dermatitis refractory to dupilumab but markedly responsive to baricitinib. Honda R, Suenaga A, Nakahara T, Shibata-Kikuchi S, et al. Eur J Dermatol 2022;32:649-650.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Honda R, Suenaga A, Nakahara T, Shibata-Kikuchi S, et al. Atopic dermatitis refractory to dupilumab but markedly responsive to baricitinib. Eur J Dermatol 2022;32:649-650.
PMID: 36468736